Study Explains Why Immunotherapy Could Trigger Colitis in Cancer Patients
Immunotherapy is a relatively new type of cancer treatment that involves strengthening the immune system and boosting its ability to identify and kill cancer cells. A recent study has found that a type of immunotherapy called checkpoint inhibitors, which prevent checkpoint proteins from binding with partner proteins, can also induce immune-related adverse events (irAEs) in cancer patients. Although immune checkpoint inhibitors have exhibited significant promise in cancer treatments, checkpoint inhibitor-induced toxicities can affect virtually any organ after treatment. Scientists have now found that colitis is one of the most common and severe toxicities that occur in cancer patients who undergo…